

## **AllerGenis Granted Rights to Develop and Market Its Precision Food Allergy Diagnostic Using Luminex xMAP® Technology**

*Food allergy diagnosis, assessment, and monitoring sensitivity will more than triple using precision, multiplexed immunoassay technology*

**Hatfield, PA January 16, 2019** — Data-driven food allergy diagnostics company, AllerGenis, LLC today announced that it has entered into a non-exclusive agreement with Luminex Corporation (NASDAQ: LMNX). According to the terms, AllerGenis will have the rights to develop, market and sell its novel precision food allergy diagnostic assay using Luminex's xMAP® Technology.

The agreement supports the upcoming 2019 commercialization of AllerGenis' food allergy diagnostic platform, which more than triples diagnostic precision compared to current food allergy tests. AllerGenis' high-throughput, peptide-bead assay breaks down allergenic proteins into smaller components, called epitopes. It then measures the reactivity of a patient's antibodies to each epitope to generate a detailed reactivity profile that can provide clinicians a comprehensive solution with accurate information to better assess and manage that patient's food allergies.

"Adopting Luminex's bead-based xMAP® technology dramatically increased the power and scope of our food allergy diagnostic," said Jim Garner, CEO and board member of AllerGenis. "We have been able to scientifically demonstrate the ability to identify food allergies with much higher precision over currently available blood tests. We're very excited to enter into this agreement with Luminex to bring this much-needed technology to the clinical setting as soon as possible."

AllerGenis' peanut allergy assay will be the first product to launch supported by this agreement in the fall of 2019. The company is also developing a pipeline of assays across a wide range of food allergens using its epitope-based technology, as well as novel biomarkers. In its full development, the goal of AllerGenis' technology will be to:

- Diagnose patient food allergy and associated severity (including anaphylaxis) without the risks associated with direct exposure to the allergen
- Distinguish between sensitivity and allergic disease, and who will naturally outgrow their condition
- Assess, manage and monitor progress of therapy (e.g. desensitization)
- Determine therapeutic efficacy (e.g. tolerance threshold)

### **About AllerGenis**

Established in 2017 and located in Hatfield, PA, AllerGenis develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess and monitor patients with food allergies. The company was founded out of a collaboration between

Genisphere, provider of the 3DNA® platform for targeted drug delivery, and Hugh Sampson MD, of the Elliot and Roslyn Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai. AllerGenis' proprietary epitope mapping technology is based on immunological research by Dr. Sampson and leverages Genisphere's expertise in improving sensitivity of diagnostic tests. AllerGenis is creating the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights.

For more information, visit [AllerGenis.com](http://AllerGenis.com).

### **About Luminex Corporation**

Luminex's mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and delivers certainty with a seamless experience. To learn more about Luminex, please visit [www.luminexcorp.com](http://www.luminexcorp.com).

### **Media Contact**

Joseph Salerno  
Director, PR and Scientific Communications  
HDMZ, Inc.  
[joseph.salerno@hdmz.com](mailto:joseph.salerno@hdmz.com)

### **Investment contact**

Russ Fein  
646-572-0421  
Corporate Fuel Partners  
[russ@corporatefuel.com](mailto:russ@corporatefuel.com)